



MaaT Pharma announces the creation of its Scientific Advisory Board (SAB)

Lyon, 2nd June 2016 – MaaT Pharma, a leader in the intestinal microbiome industry and pioneer in Autologous Faecal Microbiotherapy, today announced the creation of its international Scientific Advisory Board of acknowledged experts in the fields of intestinal microbiome, haematology, gastroenterology, bacteriology and clinical trial methodology.

The purpose of the Board will be to assist MaaT Pharma in its development, to expand and enrich its medical vision in such areas as the correction of dysbiosis and its associated complications, the eradication of Multi-Drug Resistant Bacteria, and the prevention of nosocomial diseases. It will notably formulate recommendations to enable MaaT Pharma to expand the use of its autologous microbiotherapy technology to the development of solutions for the correction of dysbiosis in designated therapeutic areas.

The MaaT Pharma Scientific Advisory Board includes recognised experts among its members: Professor **Antonio Gasbarrini**, Professor of gastroenterology at the Catholic University of Rome and a stakeholder in several governance bodies within EAGEN (European Association of Gastroenterology Endoscopy and Nutrition), EHMSG (European Helicobacter Microbiota Study Group), and UEG (United European Gastroenterology), Professor **Jean-Luc Harousseau**, former President of HAS (the French Healthcare High Authority), head of haematology Department at CHU Nantes and Director of the “Institut de Cancérologie René Gauducheau” (Nantes), Doctor **Etienne Ruppé**, Pharm.D., expert in Microbiology and specialist of Multi-Drug Resistance in Bacteria and research scientist at the Genomic Research Laboratory (Geneva), Doctor **Pascale Maisonneuve**, MD with a speciality in biochemistry and haemostatic physiology, most recently head of the “Anti-infectious drugs, hepato-gastroenterology and dermatology, rare metabolic diseases” department of ANSM (National Security Agency of Medicines and Health products), Doctor **Joël Doré**, Doctor of intestinal microbiology, Director of Research at INRA and Scientific Director of MetaGenoPolis, President of the Gut Microbiota For Health platform of the European Society of Neurogastroenterology and Motility, author of numerous scientific papers on intestinal dysbiosis, and lastly Professor **Mohamad Mohty**, director of Clinical haematology and cellular therapy at Saint Antoine hospital, President of the EBMT (European Society for Blood and Marrow Transplantation) and one of the ten most published authors in haematology in the past ten years. The Scientific Advisory Board is chaired by **Philippe Lehert**, statistical consultant for drug authorisations at the United Nations (WHO), EMA and the FDA, Professor at the University of Melbourne and the University of Louvain.

“The formation of the Scientific Advisory Board is an important step in the development of MaaT Pharma, just as we are preparing to launch our first clinical trials. We can be proud that renowned experts like those on our Scientific Advisory Board give us their support to enable us to demonstrate the effectiveness of our autologous microbiotherapy approach,” said **Corentin Le Camus**, Therapeutics Development Director of MaaT Pharma.

“The contribution of the Scientific Advisory Board is crucial to allow us both to achieve the rapid growth objectives that we have set for ourselves, and identify the diseases for which our reliable and safe therapeutic approach, will be able to offer new solutions,” commented **Hervé Affagard**, Chief Executive and founder of MaaT Pharma.





MaaT Pharma: bringing to market the first autologous faecal microbiotherapy to restore human-microbe symbiosis

Since its creation at the end of 2014, MaaT Pharma has experienced exponential growth, with €16m raised. MaaT Pharma already succeeded in validating the safety profile and dose effect of its proposed drug in the preclinical phase, during trials conducted in 2015 in partnership with Inra. It is planning its first human trials in summer 2016.

The start-up also just completed prototyping of a unique solution for collection of the harvested microbiota that guarantees the safety of all players (patient, operator, medical personnel), through to the administration phase.

The company is a pioneer in the **autologous faecal microbiotherapy** segment and benefits from the support of scientific, industrial and financial partners: Seventure Partners and INRA, its longstanding partners, CM-CIC Innovation and Biocodex laboratory, a pharmaceutical company specialised in the therapeutic fields of gastroenterology, neuropsychiatry and pain treatment.

About MaaT001

MaaT001 is the first faecal microbiotherapy GMP platform in Europe. It is available, standardized and enables the production of drugs based on a simple microbiome samples. MaaT001 is a major step forward in the treatment of dysbiosis and its associated complications.

About MaaT Pharma

MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment promotes dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.

For more information: www.maatpharma.com

Follow us on Twitter: [@MaaT_Pharma](https://twitter.com/MaaT_Pharma)

Follow us on LinkedIn: <http://www.linkedin.com/company/maat-pharma>

Key dates of MaaT Pharma

December 2014: creation.

July 2015: €2 million fundraising.

September 2015: winner of the Worldwide Innovation Contest (€1.2m).

November 2015: validation of the pre-clinical phase of its autologous microbiotherapy solution.

February 2016: selected for the TOP10 Big Booster (final in April 2016).

March 2016: €10 million fundraising.

Upcoming MaaT Pharma events

6-9 June 2016: MaaT Pharma will participate in the international congress of the Biotechnologies Innovation Organisation (BIO), in San Francisco.

28-30 June: MaaT Pharma will take part in the Microbiome Drug Development Summit in Boston.

*

**

Press Contact :

presse@maat-pharma.com

